FDA and EMA Approval: Ascentage Pharma received clearance from the FDA and EMA to launch the POLARIS-1 Phase III study, evaluating olverembatinib combined with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients.
Global Study Design: The POLARIS-1 trial is a global, multicenter, randomized, controlled, open-label study aimed at assessing the efficacy and safety of olverembatinib, with simultaneous patient enrollment across multiple countries.
Previous Approvals: This is the second global Phase III study of olverembatinib approved by US and European regulators, with the trial also initiated in China after clearance from the China Center for Drug Evaluation.
Licensing Agreement with Takeda: Ascentage signed an exclusive option agreement with Takeda for olverembatinib, allowing Takeda to potentially license global rights for development and commercialization outside of certain Asian territories.
Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 15.940
Low
18.00
Averages
18.00
High
18.00
Current: 15.940
Low
18.00
Averages
18.00
High
18.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$97
2025-12-30
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$97
AI Analysis
2025-12-30
maintain
Buy
Reason
H.C. Wainwright says Xoma (XOMA) took "a nice ride down the creativity road again with nice pipeline expansion," after the company announced an expanded relationship with partner Takeda (TAK). The deal with Takeda is highlighted by no cash out from Xoma for bringing in nine assets, the firm notes. This was accomplished by only marginally reducing Xoma's royalty/milestone share in Takeda's mezagitamab. Wainwright maintains its positive view here on the depth and breadth of Xoma's partnered assets as well as the ongoing creativity of transaction the company consummates, and looks forward to a transactional and royalty growing 2026. The firm has a Buy rating on Xoma with a price target of $97 on the shares.
JPMorgan
Neutral
maintain
$34 -> $35
2025-09-09
Reason
JPMorgan
Price Target
$34 -> $35
2025-09-09
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Alkermes (ALKS) to $35 from $34 and keeps a Neutral rating on the shares. The firm sees see alixorexton as well-positioned in narcolepsy type I based on detailed results from the Phase II Vibrance-1 study. Alixorexton delivered a profile broadly inline with expectations with efficacy that generally looks better than Takeda's (TAK) Phase III data for oveporexton, the analyst tells investors in a research note. JPMorgan upped its probability of sucess for alixorexton in narcolepsy type I to 75% from 70% following the data.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TAK
Unlock Now
Needham
Buy
downgrade
$45 -> $43
2025-09-09
Reason
Needham
Price Target
$45 -> $43
2025-09-09
downgrade
Buy
Reason
Needham lowered the firm's price target on Alkermes (ALKS) to $43 from $45 and keeps a Buy rating on the shares following Phase 2 data from the Vibrance-1 study. The firm reduced aliorexton's peak market share in narcolepsy type I by 10% to reflect its safety profile of blurred vision adverse events. The events may dissuade some physicians from using aliorexton as their first choice, especially in narcolepsy type I, given Takeda's (TAK) first-to-market position, the analyst tells investors in a research note. However, Needham continues to see valuation upside for Alkermes, believing alixorexton can have meaningful market share.
BofA
BofA
Neutral
maintain
2025-07-21
Reason
BofA
BofA
Price Target
2025-07-21
maintain
Neutral
Reason
BofA keeps a Neutral rating on Alkermes (ALKS) after the company reported Phase 2 results from the Vibrance-1 study evaluating its orexin-receptor 2 agonist in narcolepsy type1 patients. The study validates ALKS2680 as an active drug in narcolepsy, the analyst tells investors in a research note. However, the press release provided limited details on effect size and safety, which leaves outstanding questions such as strength of the cataplexy data and competitiveness versus Takeda's (TAK) TAK-861, contends BofA. The firm cites the limited data disclosure to the stock's selloff today. Alkermes in morning trading is down 7% to $27.09.
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
